Skip to content

PRTO: Held by 6 Biotech Hedge Funds (2026) | BiotechEdge

Catalysts Convergence Squeeze SignalsNEW Cash Runway Insiders M&A Research

Sign In Start 14-Day Free Trial

Home›Companies›Protara Therapeutics, Inc. (PRTO)

Protara Therapeutics, Inc.

PRTO

Held by 6 specialist biotech funds

High Convergence

6 funds opened new positions. Next phase2 readout (TARA-002): Dec 2025.

Share

Asset ManagementIPO: 2026

The RCN Pareto Strategic Allocation ETF (the Fund) seeks long-term capital appreciation.

Score Holdings Short Interest Catalysts Insiders Research

B

BiotechEdge

Catalysts Conferences Companies Convergence Fund Insiders Signals Squeeze Cash Runway Research Weekly Briefs 13F Changes Glossary PricingSign In Start 14-Day Free Trial

Data sourced from SEC EDGAR and ClinicalTrials.gov. Not investment advice.

Signal Score

5.5/10

6 funds opened new positions●●

No recent insider activity●●

Phase3 readout expected Jun 2027●●

Held by 6 specialist funds●●

See how each signal contributes— fund overlap, insider activity, catalyst timing, short interest (free trial)

Conviction + Catalyst

6 specialist funds hold PRTO with a Phase 3 in 412 days for Choline Chloride for Injection (Choline Deficiency, Liver Injury)

+2 more upcoming catalysts

OrbiMed Advisors RA Capital Management Perceptive Advisors Driehaus Capital Baker Bros. Advisors Boxer Capital

Fund Holdings

6 fund convergence

OrbiMed Advisors

RA Capital Management

Perceptive Advisors

Driehaus CapitalHeld 2Q ↑

Baker Bros. AdvisorsHeld 7Q ↑

Position history (shares)

RA Capital Management

5Q

Driehaus Capital

4Q

Baker Bros. Advisors

7Q

Boxer Capital

2Q

AI Signal

Signal: RA Capital Exit from PRTO

RA Capital's exit from Protara is notable given strong specialist fund conviction elsewhere (6 funds hold including OrbiMed, Boxer Capital, Baker Bros.). The divergence suggests potential concerns about TARA-002's path in bladder cancer (Phase 3 readout pushed to 2028) or the commercial viability of the choline deficiency program, despite multiple near-term catalysts.

Unlock full AI analysis — 14-day free trial

7 quarters

Position Trend

Aug 6, 2025

$0

0 funds

Aug 14, 2025

$4.8M

2 funds

Nov 14, 2025

$4.3M

2 funds

Feb 17, 2026

$11.9M

2 funds

+1012% total institutional value over 22 quarters

Catalysts

Phase 2Q4 2025TARA-002Lymphatic MalformationNCT05871970

Phase 3Q2 2027Choline Chloride for InjectionCholine Deficiency, Liver InjuryNCT06910943

Phase 3Q2 2028TARA-002Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma, Non-muscle Invasive Bladder Cancer With Carcinoma in SituNCT07480356

Phase 2Q2 2030TARA-002Non-muscle Invasive Bladder CancerNCT05951179

Be first to know when this name moves

Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.

Activist Filings

SC 13G/ARA Capital Management4.9%Aug 14, 2025

SC 13G/ARA Capital Management9.9%Feb 14, 2025

SC 13GRA Capital Management10.0%Apr 25, 2024

SC 13G/AOrbiMed Advisors0.0%Feb 14, 2024

SC 13G/AOrbiMed Advisors6.0%Feb 14, 2023

SC 13G/ARock Springs Capital0.0%Feb 15, 2022

SC 13GOrbiMed Advisors6.0%Feb 11, 2022

SC 13G/ARock Springs Capital5.7%Feb 16, 2021

SC 13GRock Springs Capital6.2%Oct 2, 2020

Position Details

OrbiMed AdvisorsEXITFeb 17, 2026

Start free trialfor share counts, dollar values & AI analysis

59 more position changes — start your free trial to see dollar values and AI analysis for all of them.

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 14-Day Free Trial — $29/mo

Insider Signals

No insider purchases or sales detected in the past 90 days.

Also Held by These Funds

ACRV1 fund ALGS1 fund NUVL1 fund PHVS1 fund PRLD1 fund TSHA1 fund XENE1 fund IRON1 fund

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Related Research

Verdad's Biotech White Paper, Part 1: Why Specialist Fund Holdings Predict Returns

6 min read

Verdad's Biotech White Paper, Part 2: Why Traditional Quant Factors Fail — and What Works Instead

6 min read

Fund Convergence: The Highest-Conviction Signal in Biotech Investing

5 min read

Track specialist biotech funds, insider signals, and AI analysis

Start 14-Day Free Trial

Get free weekly alerts on fund moves and catalysts: